Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lantheus

97.21
-0.2100-0.22%
Post-market: 94.87-2.3353-2.40%18:32 EDT
Volume:764.70K
Turnover:74.02M
Market Cap:6.67B
PE:22.30
High:98.70
Open:95.10
Low:93.67
Close:97.42
Loading ...

Company Profile

Company Name:
Lantheus
Exchange:
NASDAQ
Establishment Date:
1956
Employees:
808
Office Location:
201 Burlington Road,South Building,Bedford,Massachusetts,United States
Zip Code:
01730
Fax:
978 671 8860
Introduction:
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Directors

Name
Position
Brian Markison
Non-Executive Chairman of the Board
Mary Anne Heino
President and Chief Executive Officer, Director
Frederick Robertson
Director
Gary J. Pruden
Director
Gerard Ber
Director
Heinz Mausli
Director
James H. Thrall
Director
Julie H. McHugh
Director
Samuel Leno
Director

Shareholders

Name
Position
Mary Anne Heino
President and Chief Executive Officer, Director
Carol Walker
Senior Vice President, Quality
Etienne Montagut
Senior Vice President, Corporate Development
Michael Duffy
Senior Vice President, Law and Public Policy and General Counsel
Robert J. Marshall, Jr.
Chief Financial Officer
Istvan Molnar
Chief Medical Officer
John Bolla
Chief Operations Officer
Linda Lennox
Vice President, Corporate Communications
Paul Blanchfield
Chief Commercial Officer